← All trials
NCT06440629
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 20, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Jun 4, 2024
- Last posted
- Oct 18, 2024
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Diakonhjemmet HospitalLead sponsor
- University of StavangerCollaborator
- University of OsloCollaborator
- University of BergenCollaborator
- Lillehammer Hospital for Rheumatic DiseasesCollaborator
- Martina Hansen's HospitalCollaborator
- Betanien HospitalCollaborator
- South-Eastern Norway Regional Health AuthorityCollaborator
- Medical University of ViennaCollaborator
- Diakonhjemmet HospitalOfficial
- University of LondonCollaborator
- Drammen sykehusCollaborator
- Nordland HospitalCollaborator
- Norwegian University of Science and TechnologyCollaborator
- Helse Møre og Romsdal HFCollaborator
- Hospital of Southern Norway TrustCollaborator
- University Hospital of North NorwayCollaborator
- Haugesund HospitalCollaborator
- Karolinska InstituteCollaborator
- Vestre Viken Ringerike SykehusCollaborator
- Carol Davila University of Medicine and PharmacyCollaborator
- University of GothenburgCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.